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Abstract
Background: ChromograninA in prostate carcinoma (PC) indicate NE differentiation. This tumour is more
aggressive and resistant to hormone therapy.
Patients and methods: We analyzed the incidence of pre-operative ChromograninA serum levels in non
metastatic PC patients. Serum PSA and ChromograninA were analyzed before treatment. Clinicopathological
parameters were evaluated in relation to serum ChromograninA. 486 patients were enrolled.
Results: We found 352 pT2 and 134 pT3. 21 patients were N+. 278 patients had Gleason score levels <7; 173
patients had levels = 7 (122 were 3+4 and 51 4+3); and 35 patients with levels >7. Median PSA pre-operative level
was 7.61 ng/ml. PSA was significantly associated with pT stage (pT2 with PSA abnormal 23.6% vs pT3 48.5%, p <
0.0001) and with a Gleason score (PSA abnormal 60% in the Gleason score was >7 vs 29.5% in the Gleason score =
7 vs 27.3% in the Gleason score <7, p < 0.0001). In 114 patients pre-operative ChromograninA levels were elevated
(23.5%). Serum ChromograninA levels had no significant association with PSA (p = 0.44) and pT stage (p = 0.89).
abnormal ChromograninA levels increased from a Gleason score of <7 (25.5%) to >7 (31.4%) (p = 0.12). The serum
ChromograninA levels in the two groups of patients were subdivided before and after 2005 on the basis of
different used assays, showing no correlation with serum ChromograninA and other parameters.
Conclusions: This study showed that ChromograninA levels correlated to NE differentiation and possible
aggressiveness of PC. Pre-operative circulating ChromograninA could complement PSA in selecting more
aggressive PC cases, particularly in the presence of a higher Gleason score. Complementary information is provided
by the absence of a correlation between serum ChromograninA and PSA levels.
Background
Prostate cancer (PC) has become the most prevalent
malignant tumour in men in the Western World and
the second leading cause of male cancer-related death.
Initially, most tumours present androgen-sensitive carci-
nomas but the proportion of undifferentiated histology
becomes more apparent when correlated to clinical pro-
gression and the development of hormone resistance
occurrence [1,2]. The explanation of the conversion of a
hormone-sensitive status to a hormone-insensitive one
is currently one of the most critical areas of debate in
prostate carcinoma. Prostate specific antigen (PSA) is at
present the better pre-treatment predictor of the disease
and of its outcome after treatment. However, its sensi-
tivity and specificity are not yet sufficient to make it the
perfect screening test for prostate cancer. Prostate
tumour is composed of a heterogeneous population of
cells with different levels of androgen dependency.
A decline in serum PSA does not always indicate a cure
of cancer, as PSA production is androgen dependent
and as a result the dedifferentiation of neoplastic cells
gradually lose their capacity to produce PSA. Conse-
quently, serum PSA is less reliable as a tumour marker
in patients with high tumour grades and in hormonally
treated patients with disseminated disease.
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NE features. NE cells are found in all stages of prostate
cancer and are “freely” dispersed throughout the tumour.
Independent groups of researchers have shown that NE
cells lack or do not express the androgen receptor [3].
NE cells produce specific proteins, such as neuron speci-
fic enolase (NSE), chromograninA (CgA), bombesin, ser-
otonin, somatostatin, a thyroid-stimulating-like peptide,
parathyroid hormone-related peptides, and calcitonin
which are secreted into the blood stream. These NE hor-
mones have growth-factor activities on both normal and
malignant prostatic tissues. A number of them have also
been shown to activate or be activated by oncogenes, as
well as being functionally related to oncogenes [4,5]. NE
cells may also have a paracrine impact on the stroma cell
growth factor release [4]. It has been hypothesized that
the paracrine effect of the neurosecretory cell products
on adjacent cells can contribute to the growth and differ-
entiation of prostatic cells. In fact, stromal growth fac-
tors, such as epithelial growth factor (EGF), insulin-like
growth factor (IGF), fibroblast growth factor (FGF) bal-
ance changes may be responsible for the progression of
prostate cancer too [6]. Thirteen years ago, Kadmon et
al. reported that circulating CgA, main NE product, was
elevated in 48% of subjects with metastatic prostate can-
cer [7]. This evidence highlighted the importance of
serum CgA monitoring in prostate cancer patients [7].
ChromograninA is an excellent marker of NE cells and of
neuroendocrine differentiation (NED) in prostate carci-
nomas either in terms of tissue or the blood stream [3].
The detection of this markeri nt h eb l o o do fp a t i e n t s
with prostate cancer indicates a NED, either of a primary
tumour or an association with a metastases [8]. Tumours
displaying NE features are reported to be more aggressive
and resistant to hormone therapy [9]. Some authors
claimed that CgA is an independent prognostic marker
in clinical under-staging of PC [10], while others failed to
find this correlation [11]. Many groups have attempted to
identify risk factors that could help to early detect more
aggressive PC such as those with NE characteristics. The
knowledge of such risk factors could facilitate the clinical
management of such tumours and prolong survival.
The aim of our study was to analyzed the incidence of
pre-operative circulating CgA in a population of non
metastatic prostate cancer patients. Serum PSA levels,
pathological staging and the Gleason score were also
evaluated.
Methods
This is a single centre study.
The present retrospective study examined data of 740
consecutive patients with clinically non-metastatic pros-
tate adenocarcinoma that were enrolled from 2003 to
2006 at the Urology Department of our Institute for
radical prostatectomy (RRP).
Inclusion criteria considered were:
￿ No previous hormonal or radiation therapy
￿ No previous surgery on the prostate gland
￿ Histologically proven adenocarcinoma of the pros-
tate at biopsy and confirmed at RRP.
￿ No positive surgical margins.
￿ One hundred ten (14.9%) patients were excluded
from the study for missing data.
￿ One hundred forty four (19.5%) patients were not
considered as they were submitted to neoadjuvant
hormonal therapy.
A total of 486 patients were included in the present
analysis and were evaluated for all the variables consid-
ered (pathologic tumour stage, tumour grade, serum
total PSA and CgA, age).
None of these patients had previous or concomitant
history of other malignant disease, adrenal incidentalo-
mas, hepatic and/or renal impairment and/or uncon-
trolled blood hypertension.
Similarly, none of the patients were taking drugs
known to alter the metabolism and secretion of CgA,
such as nitrates and proton pump inhibitors.
An informed consent form was obtained from all
patients for all the procedures carried out. The investi-
gation was approved by the local ethical committee.
All patients had a biopsy clinically proven T2-T3 N0
M0 prostate adenocarcinoma, as determined by digital
rectal examination, transrectal ultrasonography, bone
scan, and computed tomography (CT).
All patients were submitted to RRP.
All RRP specimens were evaluated at our Institute
according to routine procedure by the same expert
uropathologist.
In all patients the tumour stage was assigned accord-
ing to the 2002 TNM classification [12].
The tumour grade was described at RRP according to
the Gleason score grading system [13].
Blood specimens were obtained in all patients in the
early morning, after an overnight fast.
In all patients a blood sample was collected in the
early morning, after an overnight fast for the determina-
tion of serum total PSA and CgA. All samples were
obtained at least 3 weeks after any prostate manipula-
tion before the surgical procedure.
Blood for serum total PSA and CgA assessments was
collected in a frozen vial until plasma separation.
All serum and plasma samples were immediately fro-
zen and stored at -20 C until analysis.
ChromograninA was measured with the enzyme-linked
immunoabsorbent assay (ELISA-DakoCytomation, Italy)
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(CGA-RIACT, CIS BIO INTERNATIONAL-France)
thereafter.
Chromogranin A ELISA Kit is designed for the quan-
titative determination of CgA in human plasma (EDTA
or heparin). The kit can be used for measuring CgA in
the 10 to 500 U/L range. The ELISA kit is a double
antibody sandwich assay where samples and conjugates
are incubated simultaneously in antibody-coated wells.
The imprecision of the assay is less than 9% over the
whole measuring range.
CGA-RIACT is a solid-phase two site immunoradio-
metric assay. Two monoclonal antibodies were prepared
against sterically remote sites on the CGA molecule.
The first one was coated on the solid phase (coated
tube), while the second one, was radio-labelled with
iodine 125, and used as a tracer.
CGA (molecules or fragments) present in the standard
or samples to be tested were “sandwiched” between the
two antibodies. Following the formation of the coated
antibody/antigen/iodinated antibody sandwich, the
unbound tracer was easily removed by washing it. The
radioactivity bound to the tube was in proportion to
the concentration of CGA present in the sample.
Reference serum values of 95% of 162 presumed nor-
mal individuals were between 19.4 and 98.1 ng/ml, with
the median at 41.6 ng/ml. The detection limit of this kit
was 1.5 ng/ml. The inter-assay and the intra-assay coef-
ficient of variation of CgA assay was 5.8% and 3.8%,
respectively. The normal reference value reported by the
kit for CgA was <98.1 ng/ml.
The reference upper value of CgA for the two assays
was 20 U/L and 90 ng/ml, respectively.
For each patient, the same serum sample was also
used to determine total PSA levels (Total PSA Elecsys-
Roche).
All samples were evaluated in the laboratory of the
Clinical Pathology Laboratory at our Institute.
After RRP, patients were all followed with PSA deter-
mination (monthly during the first year and thereafter
every 3 months), bone scan (yearly), CT or MNR (yearly
or at PSA progression).
According to literature [14], biochemical PSA progres-
sion was defined as the first occurrence of a PSA
increase over 0.2 ng/ml, with a value confirmed at two
consecutive determinations with a two week interval.
Statistical analysis
For the statistical analysis, patients were classified on the
basis of the pathological T stage in pT2 and pT3
patients (no pT4 was found and only 21 patients showed
N+ disease).
On the basis of RRP, Gleason score patients were clas-
sified in a Gleason score of <7, Gleason score = 7 and >7.
ChromograninA values were standardized in order to
obtain homogeneous data for the statistical evaluation.
Based on the pre-operative serum PSA levels and pre-
vious experience in literature [15], our patients were
subdivided in ≤10.0 ng/ml and >10.0 ng/ml.
Descriptive statistics (median, mean, range, standard
deviation) were used to characterize the population.
Categorical variables were assessed by the Pearson Chi-
square test. Student’s t-test was used to compare mean
values. Spearman correlation coefficients were calculated
to measure the association among CgA and other para-
meters. A p value ≤ 0.05 was considered statistically
significant.
All statistical analyses were performed by the SS ver-
sion 13.0
Results
The clinical and pathological characteristics of our
population are described in Table 1.
Table 1 Clinical and pathological characteristics of PC
patients
Number of cases 486
Age (yr)
Median 64 (range 44-75)
Preoperative Serum PSA (ng/ml)
Median 7,61 (range 0,75-125)
Preoperative serum PSA ≤10 ng/ml
Number of cases 148 (30.5%)
Preoperative serum PSA >10 ng/ml
Number of cases 338 (69.5%)
Preoperative Serum CgA (U/L)
Number of cases 216
Mean value 25.24 ± 39.21(range 2-340)
Median value 14
Cg A > 20 U/L 64
Preoperative Serum CgA (ng/ml)
Number of cases 270
Mean value 79.26 ± 100.50 (range 12-1064)
Median value 55







Histological Gleason score < 7 278 (57.2%)
Histological Gleason score = 7 173 (35.6%)
Histological Gleason score >7 35 (7.2%)
Appetecchia et al. Journal of Experimental & Clinical Cancer Research 2010, 29:166
http://www.jeccr.com/content/29/1/166
Page 3 of 5The present study included 486 patients (median age
64 yrs, ranging from 44-75).
The TNM classification staging were found to be 352
pT2 (72.4%) and 134 pT3 (27.6%).
Twenty one patients (4.3%) showed regional lymph
node disease (N+).
The histology tests examined found 278 tissues with a
Gleason score of <7 (57.2%); 173 with a Gleason score =
7( 3 5 . 6 % ) ,o ft h e s e1 2 2h a das c o r eo f3 + 4( 7 0 5 %a n d5 1
with a 4+3 (29.5%) and 35 with a Gleason score of >7
(7.2%).
The median PSA circulating pre-operative level was
7.61 ng/ml (range 0.75-125).
One hundred forty eight patients (30.5%) had a pre-
operative PSA ≤10 ng/ml; 338 patients (69.5%) had a
PSA > 10 ng/ml.
PSA was significantly associated with pT stage (pT2
with PSA abnormal 23.6% vs pT3 48.5%, p < 0.0001)
and Gleason score (PSA abnormal 60% in the Gleason
score >7 vs 29.5% in the Gleason score = 7 vs 27.3% in
the Gleason score <7, p < 0.0001).
In 114 patients pre-operative circulating CgA levels
were elevated (23.5%).
The serum CgA levels had no significant association
with PSA (p = 0.44) and pT stage (p = 0.89).
Classifying cases on the basis of the Gleason score
(> 7 vs =7vs < 7), abnormal CgA levels increased from
a Gleason score of <7 (25.5%) to a Gleason score of >7
(31.4%) (p = 0.12).
In addition, the statistical analysis of serum CgA
levels, were carried out separately in the two groups of
patients and were then subdivided before and after 2005
(on the basis of a different used assay), showing no cor-
relation among serum CgA and other parameters.
Discussion
Neuroendocrine (NE) differentiation frequently occurs
in common prostate malignancies and it is attracting
increasing attention in prostate cancer research. Vir-
tually all prostate adenocarcinomas show NE differentia-
tion as defined by the NE marker chromograninA.
Angelsen et al. reported that CgA positive tumours pre-
senting high serum CgA levels, suggested that the CgA
should be a useful marker for predicting the extent of
NED in prostate cancer [16]. NE differentiation, how-
ever, occurs only in the G0 phase of the cell cycle when
tumour cells are usually resistant to cytotoxic drugs and
radiotherapy. Even NE tumour cells do not proliferate,
they produce NE growth factors with mitogenic activity
that promote cell proliferation and induce anti-apoptotic
features in non-NE cells in close proximity to NE cells
through a paracrine mechanism [17]. Neoplastic epithe-
lial cells may become more responsive to NE products
by upregulation of the neuropeptides receptors, or may
stimulate NE cells to up-regulate the secretion and
synthesis of their products [4]. Neuroendocrine tumour
cells lack androgen receptors and are androgen insensi-
tive in all stages of the disease. Even though androgen
depletion results in apoptosis of the epithelial cells, it
seems that it is not able to eliminate all cancer cells,
and over time, an androgen-independent NE population
emerges and ultimately predominates [4]. However
some authors disagree with this finding [18]. Prostate
cancer cells with NE features escape programmed cell
death [19]. Even under androgen deprivation, only
0.16% of NE tumour cells show apoptotic activity. This
indicates that NE tumour cells represent an immortal
pattern in prostate cancer. PSA is an important tool for
detecting prostate cancer. However, it was reported that
t h ed i a g n o s t i cr o l eo fs e r u mP S Ai na s s e s s i n gt h et r e a t -
ment efficacy in patients with hormone-refractory dis-
ease did not correlate with changes in pain
symptomatology and disease outcome [20]. Some
authors reported that high levels of CgA allowed prog-
nostic information independently from PSA [21], while
others failed to show the same results [6,10,11,22,23].
Neuroendocrine differentiation also appeared to be asso-
ciated with the androgen-refractory state and a poor
prognosis [6,23-26]. It was reported that prostate cancer
with a significant NE component is common in the
advanced stage of the disease, especially in those patients
who do not have elevated serum PSA levels [7,25,27,28],
but its diagnostic role in non metastatic disease is still a
matter of debate [8,29,30]. We analyzed serum CgA levels
in patients who were diagnosed with a prostate cancer
before surgery. In our population 23.5% of all patients
showed elevated pre-treatment circulating CgA levels. It is
worthy to note that our population showed pre-treatment
supra-normal CgA serum levels in the absence of distant
metastases. In our series of patients serum CgA levels had
no significant association with PSA.
According to other authors [25,31], we found that
CgA depicted a significant trend in association with
high-grade disease. We did not observe any associations
in our assessment of pathological stages.
Conclusions
According to our study, ChromograninA levels demon-
strated a correlation with NE differentiation and possible
aggressiveness of PC. This finding suggests that pre-
operative circulating CgA determination could have a
potential role in the clinical management of PC patients
and could complement the PSA assay in an early selec-
tion of more aggressive PC such as those with NE fea-
tures, particularly in those patients showing a higher
Gleason score.
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